# reload+after+2024-01-21 19:47:55.649554
address1§3980 Premier Drive
address2§Suite 310
city§High Point
state§NC
zip§27265
country§United States
phone§336 841 0300
fax§336 841 0310
website§https://vtvtherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
fullTimeEmployees§13
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jonathan L. Isaacsohn FACC, M.D.', 'age': 69, 'title': 'Executive Chairperson', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul J. Sekhri M.Sc.', 'age': 65, 'title': 'CEO, President & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 483431, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven  Tuch M.B.A.', 'age': 54, 'title': 'Executive VP & CFO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 449159, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Barry  Brown', 'age': 62, 'title': 'Chief Accounting Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 311977, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard S. Nelson', 'age': 53, 'title': 'Executive VP of Corporate Development & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 201081, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carmen  Valcarce Ph.D.', 'title': 'Chief Scientific Officer & Executive VP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Vanessa  McDade', 'title': 'Chief Administrative Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth M. Keiley', 'age': 57, 'title': 'Executive VP & General Counsel', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas  Strack M.D., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.263
priceToSalesTrailing12Months§2358.4976
currency§USD
dateShortInterest§1702598400
forwardEps§-0.33
exchange§NCM
quoteType§EQUITY
shortName§vTv Therapeutics Inc.
longName§vTv Therapeutics Inc.
firstTradeDateEpochUtc§1438263000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d1714f5e-cf59-34a6-a49a-325d1d43a409
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.0
targetLowPrice§2.0
targetMeanPrice§2.0
targetMedianPrice§2.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§0.803
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
